Es ist ein Fehler aufgetreten!
Roche Aktie
| 338.40 CHF | -7.40CHF | -2.14% |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.02 |
| Government Pension Fund - Global (the) | 2.63 |
| Vanguard Total International Stock Index Fund | 1.58 |
| Roche Holding AG | 0.97 |
| PRIMECAP Management Co. | 0.79 |
| Alecta Pension | 0.74 |
| Csif (ch) Umbrella - Switzerland Total Market Index Blue | 0.72 |
| Dodge & Cox Funds - International Stock Fund | 0.66 |
| Vanguard Developed Markets Index Fund | 0.61 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 91'747 | 94'052 | 93'734 | 94'442 | 97'735 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.52 | 0.54 | 0.57 | 0.60 | 0.63 |
Bilanz (in Mio. EUR) - Aktiva
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 28'182 | 28'670 | 31'572 | 32'244 | 31'254 |
| Summe Anlagevermögen | 44'230 | 46'266 | 45'401 | 46'392 | 48'329 |
| Summe Aktiva | 75'763 | 76'819 | 76'676 | 78'517 | 83'091 |
Bilanz (in Mio. EUR) - Passiva
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 23'251 | 22'355 | 18'960 | 18'770 | 15'582 |
| Summe Fremdkapital | 52'463 | 50'417 | 47'669 | 48'151 | 47'224 |
| Summe Eigenkapital | 23'300 | 26'402 | 29'007 | 30'366 | 35'867 |
| Summe Passiva | 75'763 | 76'819 | 76'676 | 78'517 | 83'091 |
Adresse
| Grenzacherstrasse 124, 4070 Basel | |
| Telefon | +41 (61) 688-11-11 |
| Fax | +41 (61) 691-93-91 |
| Internet | http://www.roche.com |
Management
|
Alan Hippe
Chief Financial & Information Technology Officer |
|
Andreas Oeri
Independent Non-Executive Director |
|
André S. Hoffmann
Vice Chairman |
|
Anita Hauser
Director |
|
Bernard J. Poussot
Non-Executive Director |
|
Christoph Franz
Chairman |
|
Claudia Süssmuth Dyckerhoff
Director |
|
Cristina A. Wilbur
Head-Group Human Resources |
|
Gallia Levy
Associate Group Medical Director-Hematology |
|
Gottlieb A. Keller
Secretary & General Counsel |
|
Hans Clevers
Director |
|
Jason S. Ehrlich
Senior Group Medical Director |
|
John Irving Bell
Non-Executive Director |
|
Julie Brown
Director |
|
Karl Mahler
Head-Investor Relations |
|
Karsten Jung
Global Product Strategy Head |
|
Michael D. Varney
Head-Genentech Research & Early Development |
|
Pablo Umaña
Head-Cancer Immunotherapy Discovery |
|
Paul Bulcke
Non-Executive Director |
|
Per-Olof Attinger
Secretary-Executive Committee & Head-CEO Office |
|
Richard P. Lifton
Non-Executive Director |
|
Severin Schwan
Chief Executive Officer & Executive Director |
|
Urs Jaisli
Chief Compliance Officer |
|
William Pao
Head-Pharma Research & Early Development |
